| WEE1 Inhibitor MK-1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia |
Belinostat |
WEE1 |
I |
| Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL |
Belinostat |
Radiotherapy |
II |
| Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
Panobinostat |
mTOR |
I, II |
| Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
Panobinostat |
|
II |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction |
Romidepsin |
|
I |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
Romidepsin |
Aurora Kinase |
I |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma |
Romidepsin |
CD20, immunomodulation, proliferation, angiogenesis |
I, II |
| Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma |
Romidepsin |
Immunomodulation, proliferation, angiogenesis |
II |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
Vorinostat |
Aurora Kinase |
I |
| Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas |
Vorinostat |
CD20 |
I, II |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma |
Vorinostat |
Proteosome |
II |
| Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia |
Vorinostat |
DNA synthesis, Topoisomerase II |
III |
